Is GSK stock a Buy, Sell, or Hold?

Based on our analysis, GSK is currently a HOLD with moderate confidence. 📊 HOLD: GSK is fairly valued with market pricing in 1.0% annual growth. Fine to hold or accumulate slowly on dips.

What is the fair value of GSK stock?

Our analysis estimates the fair value range for GSK to be between $48.69 and $50.89. The current price is $52.61.

What is the analyst price target for GSK?

The average Wall Street analyst price target for GSK is $52.35. This implies a potential upside of 1.5% from current levels.

GSK Stock Analysis: Buy, Sell, or Hold?

GSK - GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Pharmaceutical Preparations

$52.61

1.01 (1.96%) ▲

5d: +4.55%

30d: +7.28%

90d: +12.08%

HOLD

MODERATE Confidence

Last Updated: January 30, 2026

Earnings: Feb 04, 2026 1d

Get Alerted When GSK Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 HOLD: GSK is fairly valued with market pricing in 1.0% annual growth. Fine to hold or accumulate slowly on dips.

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: 7.0%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$65.47

Based on 5.5% avg growth

INTRINSIC VALUE TODAY

$40.65

Trading above fair value

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.4x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: GSK is currently trading at $52.61, which is considered extended relative to its 30-day fair value range of $48.69 to $50.89. The stock's valuation (Forward PE: 10.7) is in line with its historical norms (10.4). At these levels, the market is pricing in 1.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.

Technical Outlook: Technically, GSK is in a strong uptrend. The price is approaching resistance at $52.59. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.

Market Sentiment: GSK has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.

Quick Decision Summary

Current Position EXTENDED

Fair Price Range $48.69 - $50.89

Company Quality Score 61/100 (BUY)

Volume Confirmation HIGH

Confidence Score 58.1%

All Signals

BEARISH: Price extended above range
BULLISH: Strong technical setup (75/100)
BULLISH: High volume confirmation
NEUTRAL: Near Wall St target ($52.35)
NEUTRAL: Market pricing in 1.0% annual earnings growth - fairly valued

Fair Price Analysis

30-Day Fair Range $48.69 - $50.89

Current vs Fair Value EXTENDED

Support & Resistance Levels

Support Level $47.62

Resistance Level $52.59

Current Trend Strong Uptrend

Fundamental Context

Forward P/E (Next Year Est.) 10.71

Wall Street Target $52.35 (+1.5%)

Revenue Growth (YoY) 6.7%

Earnings Growth (YoY) 23.2%

Profit Margin 17.1%

Valuation Premium vs History +1.0% premium

PE vs Historical 10.7 vs 10.4 FAIR

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): +1.0% (market-implied from PE analysis)

1-Year Target $52.12 (+1%)

2-Year Target $52.64 (+2%)

3-Year Target $53.16 (+3%)

3-Yr Target (if PE normalizes) (PE: 11→10) PE COMPRESSION $51.63 (+0%)

Earnings growth offset by PE compression

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 22.3, Growth: 7.0%) $131.69 (+155%)

Base: (SPY PE: 10.7, Growth: 7.0%) $63.24 (+23%)

Bear: (PE: 9.1, Growth: 7.0%) $53.76 (+4%)

📈 Valuation based on Current Earnings

RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (11x PE) as earnings recover.

Trailing PE: 13.61 | Current EPS (TTM): $3.68

Bull Case $72.16 (+40%)

Analyst growth 30.9%, PE expands to 15.0

Base Case $65.60 (+27%)

Market implied 30.9%, PE stable at 13.6

Bear Case $34.07 (-34%)

Severe decline -20.0%, PE contracts to 11.6

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

Last updated: February 02, 2026 12:23 PM ET
Data refreshes hourly during market hours. Next update: 1:23 PM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is GSK showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check

Insider Activity (6 Months)

Buys

Sells

Net

INSIDERS SELLING

Recent Transactions

Val T. Hoyle SELL 2025-09-23

View Insider Activity Scanner

Top Rated Drug Manufacturers - General Stocks

Top-rated stocks in Drug Manufacturers - General by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
LLY Eli Lilly and Company	STRONG BUY 29 analysts	$1146	60 BUY
GILD Gilead Sciences Inc	BUY 30 analysts	$139	63 BUY
AMGN Amgen Inc	HOLD 32 analysts	$333	66 BUY
ABBV AbbVie Inc	BUY 28 analysts	$245	61 BUY
BIIB Biogen Inc	HOLD 37 analysts	$193	58 HOLD

LLY Eli Lilly and Com…

60 BUY

GILD Gilead Sciences I…

More Analysis for GSK

GSK Technical Chart GSK Price Prediction GSK Earnings Date GSK Investment Advisor GSK Fair Price Analyzer GSK Competitors

Compare GSK with Other Stocks

Create New Comparison

Tradestie